Copyright
©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jan 28, 2016; 22(4): 1421-1432
Published online Jan 28, 2016. doi: 10.3748/wjg.v22.i4.1421
Published online Jan 28, 2016. doi: 10.3748/wjg.v22.i4.1421
New approaches in the treatment of hepatitis C
Rocío González-Grande, Miguel Jiménez-Pérez, José Mostazo Torres, González Arjona, Liver Transplantation and Hepatology Unit, UGC de Aparato Digestivo, Hospital Regional Universitario, 29010 Malaga, Spain
Author contributions: González-Grande R, Jiménez-Pérez M, González Arjona C and Mostazo Torres J contributed equally to this work.
Conflict-of-interest statement: The authors have no conflict of interest to report.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Miguel Jiménez-Pérez, MD, UGC de Aparato Digestivo, Unidad de Hepatología-Trasplante Hepático, Hospital Universitario Regional de Málaga, Avenida Carlos Haya, 29010 Malaga, Spain. mjimenezp@commalaga.com
Telephone: +34-61-095935 Fax: +34-95-1291941
Received: May 1, 2015
Peer-review started: May 8, 2015
First decision: July 14, 2015
Revised: August 5, 2015
Accepted: October 12, 2015
Article in press: October 13, 2015
Published online: January 28, 2016
Peer-review started: May 8, 2015
First decision: July 14, 2015
Revised: August 5, 2015
Accepted: October 12, 2015
Article in press: October 13, 2015
Published online: January 28, 2016
Core Tip
Core tip: About 130-170 million people, is estimated to be infected with the hepatitis C virus. Chronic hepatitis C is one of the leading causes of liver-related death and in many countries it is the primary reason for having a liver transplant. Until a few years ago the only treatment strategy was based on the combination of pegylated interferon and ribavirin (RBV). Since 2011 the accelerated incorporation of direct acting antiviral agents has created a new scenario: increasing the rates of sustained viral response, shorter therapies, less toxicity and regimens free of interferon and/or RBV and can even modify the natural history of the disease.